Compare DexCom, Inc. (DXCM) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs J M Smucker Co — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while J M Smucker Co trades at $109.02 (market cap $11.65B). The key difference: DexCom, Inc. is far larger — about 2.4× J M Smucker Co's market cap, and J M Smucker Co pays a 4.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SJM | |
|---|---|---|
Market Cap | $28.06B | $11.65B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $117.05 |
52-Week Low | $54.84 | $89.53 |
Enterprise Value | $27.03B | $18.68B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
J.M. Smucker (SJM) trades at $113.00, up 3.85% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $1.23 billion for 2025, with negative profit margins, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $123.18 price target, supported by strong cash flow and a 4% dividend yield. Key growth drivers include Uncrustables and coffee brands, while fiscal 2027 sales are expected to decline 3-4%.
SJM presents a mixed outlook: valuation appears reasonable with a P/E of 22.05, but profitability concerns and high debt pose risks. Near-term catalysts include cost controls and brand innovation, yet competitive pressures and weak sales guidance may limit upside. The stock offers income via dividends, but investors should weigh execution risks against potential margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
